Journal Articles
2020

Outcomes of Liver Transplant Recipients with Acute-on-Chronic
Liver Failure Based on EASL-CLIF Consortium Definition: A Singlecenter Study
U. Agbim
A. Sharma
B. Maliakkal
S. Karri
M. Yazawa

See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Hepatology Commons

Recommended Citation
Agbim U, Sharma A, Maliakkal B, Karri S, Yazawa M, Goldkamp W, Podila PS, Vanatta JM, Gonzalez H,
Satapathy SK, . Outcomes of Liver Transplant Recipients with Acute-on-Chronic Liver Failure Based on
EASL-CLIF Consortium Definition: A Single-center Study. . 2020 Jan 01; 6(4):Article 7316 [ p.]. Available
from: https://academicworks.medicine.hofstra.edu/articles/7316. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic
Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara
Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors
U. Agbim, A. Sharma, B. Maliakkal, S. Karri, M. Yazawa, W. Goldkamp, P. S. Podila, J. M. Vanatta, H.
Gonzalez, S. K. Satapathy, and +3 additional authors

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/7316

Liver Transplantation

Outcomes of Liver Transplant Recipients
With Acute-on-Chronic Liver Failure Based
on EASL-CLIF Consortium Definition:
A Single-center Study
Uchenna Agbim, MD,1,2 Anuj Sharma, MD,3 Benedict Maliakkal, MD,1,2 Saradasri Karri, MD,4
Masahiko Yazawa, MD,1,2 William Goldkamp, MD,4 Pradeep S.B. Podila, PhD,5 Jason M. Vanatta, MD,6
Humberto Gonzalez, MD,7 Miklos Z. Molnar, MD,1,2 Satheesh P. Nair, MD,1,2 James D. Eason, MD,1,2
and Sanjaya K. Satapathy, MBBS, MD, DM, MS8

Background. The impact of acute-on-chronic liver failure (ACLF) defined by European Association for the Study of the
Liver-Chronic Liver Failure in liver transplant (LT) recipients has not been well characterized. The aim of the study was to
assess early posttransplant morbidity and survival of ACLF patients. Methods. Eight hundred twenty-five consecutive
LT patients (04/2006–03/2013) were included in a retrospective analysis. Of the 690 evaluable patients, 589 had no ACLF,
and the remaining 101 were grouped into ACLF Grades 1–3 (ACLF Grade 1: 50 [49.5%], ACLF Grade 2: 32 [31.7%], and
ACLF Grade 3: 19 [18.8%]). Results. LT recipients transplanted in the context of ACLF had significantly increased serum
creatinine (2.27 ± 1.16 versus 0.98 ± 0.32; P < 0.0001), and inferior 1-year graft (90% versus 78%; P < 0.0001) and patient
survival (92% versus 82%; P = 0.0004) by Kaplan-Meier survival analysis; graft and patient survival correlated negatively
with increasing severity of ACLF. One-year graft and patient survival were lower in those with high ACLF (Grade 2 and 3)
irrespective of Model for End-Stage Liver Disease compared with other groups. The ACLF group had longer intensive
care unit stays (10.6 ± 19.5 versus 4.2 ± 9; P < 0.0001), hospital stays (20.9 ± 25.9 versus 11.7 ± 11.4; P < 0.0001), and
increased surgical re-exploration (26.7 % versus 14.6%, P = 0.002). Conclusions. Patients with ACLF undergoing LT
have significantly higher resource utilization, inferior graft survival and patient survival, and renal dysfunction at 1 year. The
combination of ACLF and Model for End-Stage Liver Disease can be considered when determining the suitability for potential transplantation.
(Transplantation Direct 2020;6: e544; doi: 10.1097/TXD.0000000000000984. Published online 18 March, 2020.)

A

cute-on-chronic liver failure (ACLF) is an increasingly
recognized entity encompassing acute deterioration of
patients with chronic liver disease associated with multiple
organ failures leading to increased mortality.1 Several definitions of ACLF have been proposed; however, currently the

most accepted definition of ACLF was coined by the European
Association for the Study of the Liver-Chronic Liver Failure
(EASL-CLIF) Consortium Acute-on-Chronic Liver Failure in
Cirrhosis (CANONIC) study.2,3 The CANONIC study proposed diagnostic criteria based on patients with cirrhosis and
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acute decompensation who had organ failures and a high
28-day mortality rate.2,3 The precipitating events leading to
acute deterioration of their liver function were either secondary to superimposed liver injury or extrahepatic factors such
as infection or gastrointestinal hemorrhage.1
ACLF patients have been shown to have a high mortality according to the CANONIC study.3 Grade 1 ACLF had
a 28-day and 90-day mortality of 22.1% and 40.7%, respectively. Grade 2 ACLF had a 28-day and 90-day mortality
of 32.0% and 52.3%, respectively. Grade 3 ACLF had a
28-day and 90-day mortality of 76.7% and 79.1%, respectively. However, the posttransplant morbidity and mortality
of patients transplanted for ACLF has not been thoroughly
studied using consistent criteria. Although a few recent studies
have attempted to address this issue,4,5,6,7 more studies with
granular data are needed to better define survival outcomes in
patients with ACLF undergoing liver transplant (LT).
Our primary aim was to determine posttransplant early
survival outcomes at 90 days and 1-year in a single center
based on pretransplant ACLF severity as defined by EASLCLIF Consortium definition. We also aimed to assess several
surrogate markers for resource utilization, such as length of
hospital stay, early hospital readmissions, early surgical reexploration/interventions, and intraoperative transfusion
requirements.

MATERIALS AND METHODS
A retrospective review of 825 consecutive LT patients
between April 2006 and March 2013 at Methodist
University Hospital Transplant Institute was performed.
Patients without chronic liver disease (n = 31), retransplant recipients (n = 53), combined liver/kidney transplant
recipients (n = 35), and acute liver failure patients (n = 16)
were excluded.

www.transplantationdirect.com

Of the remaining 690 evaluable patients, 589 had no
ACLF. The final cohort of patients who met the EASL-CLIF
Consortium definition included 101 LT recipients, whom
were further subdivided into ACLF Grades 1–3 based on the
CLIF-Sequential Organ Failure Assessment (SOFA) score.
We defined “ACLF” and “ non-ACLF” using the EASLCLIF Consortium definition based on data at the time of
transplant,8,9 as follows: Non-ACLF: (1) patients with no
organ failure; or (2) patients with a single “nonkidney” organ
failure who had a serum creatinine level <1.5 mg/dL and no
hepatic encephalopathy, or (3) patients with single cerebral
failure who had a serum creatinine level <1.5 mg/dL. ACLF
Grade 1: (1) patients with single kidney failure; or (2) patients
with single failure of the liver, coagulation, circulation or respiration who had a serum creatinine level ranging from 1.5 to
1.9 mg/dL and/or mild to moderate hepatic encephalopathy,
or (iii) patients with single cerebral failure who had a serum
creatinine level ranging from 1.5 to 1.9 mg/dL. ACLF Grade
2: patients with 2 organ failures. ACLF Grade 3: patients with
3 or more organ failures. The definition of organ failure was
based on the CLIF-SOFA score.8 Liver failure was defined by
a serum bilirubin level of ≥12.0 mg/dL. Kidney failure was
defined by a serum creatinine level of ≥2.0 mg/dL or the use
of renal replacement therapy. Cerebral failure was defined by
grade III or IV hepatic encephalopathy, according to the West
Haven classification. Coagulation failure was defined by an
international normalized ratio (INR)>2.5. Circulatory failure
was defined by the use of vasopressors. Respiratory failure
was defined by the ratio of PaO2 to FiO2 of ≤200 or an SpO2
to FiO2 ratio of ≤214.
Demographic data were collected on all patients including age, race, sex, and cause of liver disease. Laboratory
data including bilirubin, creatinine, and INR were collected
to calculate the native Model for End-Stage Liver Disease

FIGURE 1. Algorithm showing methods of inclusion of the LT recipients with and without ACLF. ACLF, acute-on-chronic liver failure; LT, liver
transplant.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 1.

Clinical and demographic profile of the LT recipients with and without ACLF

Parameters
Recipient characteristics
Age, y
Mean ± SD
Median
Interquartile range
Male, n (%)
BMI, kg/m2
Mean ± SD
Median
Interquartile range
Race, n (%)
  -Caucasian
  -African American
  -Hispanic
  -Others
Etiology of LT, n (%)
  -ETOH/HCV
  -HCV
  -NASH/CC
  -AIH
  -PBC§
  -PSC§§
  -Wilson’s disease
  -Sarcoidosis
  -A1-AT disease
  -HBV
  -ETOH
  -Others
MELD score
   Mean ± SD
  Median
  Interquartile range
ALT, IU/mL
   Mean ± SD
  Median
  Interquartile range
AST, IU/mL
   Mean ± SD
  Median
  Interquartile range
ALP, IU/mL
   Mean ± SD
  Median
  Interquartile range
Total bilirubin, mg/dL
   Mean ± SD
  Median
  Interquartile range
WBC count, 103µL
   Mean ± SD
  Median
  Interquartile range
Platelet count, 103µL
   Mean ± SD
  Median
  Interquartile range

All patients

No ACLF

ACLF

N = 690

N = 589

N = 101

54.2 ± 9.2
55
49–61
467 (67.7)

54.5 ± 9.1
55
50–61
400 (67.9)

52.3 ± 9.8
54
47–60
67 (66.3)

28.9 ± 5.7
28.6
24.8–32.5

28.2 ± 5.6
28.5
24.8–32.3

29.6 ± 6.3
29.1
25–33.6

495 (71.7)
115 (16.7)
69 (10)
11 (1.6)

423 (71.8)
94 (16.0)
64 (10.8)
8 (1.4)

72 (71.3)
21 (20.7)
5 (5.0)
3 (3)

29 (4.2)
298 (43.2)
114 (16.5)
34 (4.9)
22 (3.2)
21 (3.0)
4 (0.6)
9 (1.3)
11 (1.6)
8 (1.2)
133 (19.3)
7 (1.0)

26 (4.41)
267 (45.33)
100 (16.98)
26 (4.41)
19 (3.23)
19 (3.23)
2 (0.34)
8 (1.36)
10 (1.7)
7 (1.19)
98 (16.64)
7 (1.19)

3 (2.97)
31 (30.69)
14 (13.86)
8 (7.92)
3 (2.97)
2 (1.96)
2 (1.98)
1 (0.99)
1 (0.99)
1 (0.99)
35 (34.65)
0 (0)

18.5 ± 7.6
17
13–22

16.4 ± 5.3
16
13–20

31 ± 6.9
31
27–35

55 ± 55
40
27–64

54 ± 44
40
28–64

63 ± 97
40
22–63

86 ± 73
66
46–97

84 ± 62
65
47–96

102 ± 118
74
43–114

152 ± 112
127
92–175

155 ± 105
133
97–179

131 ± 145
100
72–139

5.6 ± 7.6
3
1.8–5.7

3.9 ± 4
2.8
1.7–4.7

15.2 ± 13.9
10.5
3.7–24.4

5.5 ± 2.9
4.9
3.7–6.6

5.2 ± 2.3
4.8
3.5–6.3

7.5 ± 4.7
6.3
4.5–8.7

92 ± 59
79
58–112

93 ± 60
80
58–114

83 ± 51
69
53–107

P
0.023

0.75
0.41

0.13

0.78
0.007
0.56
0.06
1.00
0.75
0.10
1.00
1.00
1.00
<0.0001
0.60
<0.0001

0.24

0.49

<0.0001

<0.0001

<0.0001

0.07

Continued on next page

4

Transplantation DIRECT

www.transplantationdirect.com

■ 2020

TABLE 1. (Continued)

Clinical and demographic profile of the LT recipients with and without ACLF

Parameters
INR
   Mean ± SD
  Median
  Interquartile range
Serum Creatinine, mg/dL
   Mean ± SD
  Median
  Interquartile range
Donor and intraoperative characteristics
Donor age, Y
   Mean ± SD
  Median
  Interquartile range
Donor BMI, kg/m2
   Mean ± SD
  Median
  Interquartile range
Donor male gender, n (%)
Donor race, n (%)
  -Caucasian
  -African American
  -Hispanic
  -Others
DCD, n (%)
Cold ischemic time, min
   Mean ± SD
  Median
  Interquartile range

All patients

No ACLF

ACLF

N = 690

N = 589

N = 101

1.7 ± 0.6
1.6
1.3–1.9

1.6 ± 0.5
1.5
1.3–1.8

2.4 ± 0.9
2.2
1.7–2.9

1.17 ± 0.7
1
0.8–1.3

0.98 ± 0.32
0.9
0.7–1.2

2.27 ± 1.16
2.1
1.6–2.9

41.4 ± 16
43
27–54

41.8 ± 16.1
44
28–55

39.3 ± 15.5
39
25–52

27.9 ± 8.7
26.8
23–31
396 (57.4)

28.2 ± 9
27.1
23.4–31.1
332 (56.4)

26.2 ± 6.3
25
22.2–29.3
64 (63.4)

511 (74.1)
145 (21)
21 (3)
13 (1.9)
46 (6.7)

435 (73.9)
122 (20.7)
20 (3.4)
12 (2.04)
41 (7.0)

76 (75.3)
23 (22.8)
1 (0.99)
1 (0.99)
5 (5.0)

290 ± 106
278
222–350

290 ± 103
280
222–352

293 ± 125
270
225–344

P
< 0.0001

<0.0001

0.14

0.005

0.19
0.51

0.66
0.70

ACLF, acute-on-chronic liver failure; AIH, autoimmune hepatitis; Alpha-1 AT, alpha-1 antitrypsin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body
mass index; CC, cryptogenic cirrhosis; DCD, donation after cardiac death; ETOH, alcohol; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international normalized ratio; LT, liver transplant; MELD,
model for end-stage liver disease; NASH, nonalcoholic steatohepatitis; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; WBC, white blood cell count.

(MELD) score at time of transplantation, as well as to categorize patients into Grades of ACLF. ACLF Grade 2 and 3
were considered high ACLF, and a MELD score ≥30 was considered a high MELD for the purpose of this study. In addition, donor and intraoperative characteristics including use of
blood products were recorded.
Posttransplant data collected included liver enzymes,
serial serum creatinine measurements, surgical re-exploration following LT, repeat LT due to graft failure, length of
stay posttransplant, length of intensive care unit (ICU) stay
posttransplant, and liver- and nonliver-related mortality.
Considering the greatest impact on survival will be early after
LT in the ACLF group, we analyzed survival up until 1-year
post-LT separately from long-term survival (beyond 1 y).
The University of Tennessee Health Science Center
Institutional Review Board approved the study a priori.
Statistical Considerations
Descriptive statistics were calculated for all of the key variables. Continuous variables were expressed as means with
SD and categorical variables as counts with percentages.
Statistical significance was set a priori at the conventional
P ≤ 0.05. Independent sample t-tests were used to compare the
differences between mean values with Wilcoxon 2-Sample Test
applied as indicated. We used the normal approximation method

and reported 2-sided P-values. Categorical variables were evaluated by Yates corrected chi-squared tests with Fisher exact tests
applied as indicated. Survival was analyzed using Kaplan-Meier
survival curve using the log-rank tests. Survival time was counted
from time of transplant until death or retransplant. Cox proportional hazard model was used to assess predictors of survival
including variables significant on univariate analysis and those
deemed clinically significant. We examined the Variance Inflation
Factor (VIF) in determining which variables may be involved in
multicollinearity. For the ith independent variable, the variance
inflation factor is defined as 1/(1 − Ri2), where Ri is the coefficient of determination for the regression of the ith independent
variable on all other independent variables. Any variables associated with a VIF value exceeding 1/(1 − Ri2) are more closely
related to other independent variables than they are related to
the dependent variable. If high bivariate correlations are present,
and if “multicollinearity” was detected, one of the two variables
was deleted and tested in separate models. Statistical analyses
were performed using SAS Version 9.4 (SAS Institute, Cary, NC).

RESULTS
Clinical and Demographic Characteristics
One hundred and one LT recipients (14.6%) with ACLF
based on the EASL-CLIF Consortium definition were

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 2.

Early posttransplant profile of the LT recipients with and without ACLF

Parameters
Peak ALT, IU/mL
Mean ± SD
Median
Interquartile range
Peak AST, IU/mL
Mean ± SD
Median
Interquartile range
Peak ALP, IU/mL
Mean ± SD
Median
Interquartile range
Peak total bilirubin, mg/dL
Mean ± SD
Median
Interquartile range
Peak WBC post-LT, 103µL
Mean ± SD
Median
Interquartile range
Lowest platelet count, 103µL
Mean ± SD
Median
Interquartile range
Length of hospital stay, d
Mean ± SD
Median
Interquartile range
Length of ICU stay, d
Mean ± SD
Median
Interquartile range
Retransplant, n (%)
Surgical re-exploration ≤90 d, n (%)
Early readmissionsa, n (%)
Early graft loss, n (%)

All patients

No ACLF

ACLF

N = 690

N = 589

N = 101

956 ± 1123
601
296–1100

952 ± 1092
632.5
312–1126

982 ± 1301
503
243–974

2245 ± 3689
1096
563–2339

2200 ± 3062
1126
578–2426

2543 ± 6238
872
435–2095

326 ± 329
231
145–386

314 ± 309
229.5
142–383

399 ± 420
270
158–415

8.7 ± 8.4
5.7
3.3–10.5

7.9 ± 7.8
5.4
3.1–9.3

13.0 ± 10.2
10.1
5.2–17.7

13.8 ± 7.7
12.2
9.2–16.4

13.6 ± 6.9
12.2
9.2–16.1

15.2 ± 11.2
12.5
9.6–18.2

43.0 ± 28.0
36
26–51

45 ± 29
38
28–54

30 ± 17
27
18–39

13 ± 14.8
9
7–12

11.7 ± 11.4
8
7–11

20.9 ± 25.9
12
9–21

5.2 ± 11.3
2
2–3
39 (5.7)
113 (16.4)
197 (28.6)
44 (6.4)

4.2 ± 9
2
2–3
32 (5.4)
86 (14.6)
163 (27.7)
31 (5.3)

10.6 ± 19.5
3
2–6
7 (6.9)
27 (26.7)
34 (33.7)
13 (12.9)

P
0.12

0.16

0.041

<0.0001

0.34

<0.0001

<0.0001

<0.0001

0.49b
0.002
0.22
0.004

Early readmissions defined as admissions ≤90 d.
Fisher Exact test.
ACLF, acute-on-chronic liver failure; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ICU, intensive care unit; LT, liver transplant; WBC, white blood cell count.
a

b

compared with 589 LT recipients who did not met the criteria
for ACLF but had underlying chronic liver disease (Figure 1).
The demographic and clinical characteristics of these patients
are shown in Table 1. LT recipients were categorized into 3
categories of severity per EASL-CLIF Consortium definition
for ACLF: 50 (49.5%) under ACLF Grade 1, 32 (31.7%)
under ACLF Grade 2, and 19 (18.8%) under ACLF Grade
3 category. Of the included ACLF patients, 46 (45.5%) had
liver failure, 65 (64.4%) had kidney failure, 42 (41.6%) had
a coagulation failure, 13 (12.9%) had cerebral failure, 4 (4%)
had circulatory failure, and 10 (9.9%) had respiratory failure.
Overall mean CLIF-SOFA score in the ACLF group was 10.1
± 2.1. In the ACLF grade 1, ACLF grade 2, and ACLF grade 3
groups, the mean CLIF SOFA score was 9.1 ± 1, 11.5 ± 0.9,
and 13.7 ± 1.5, respectively.
LT recipients with ACLF were younger, but no significant
differences were noted in sex, race, or ethnicity. The mean
MELD score was significantly higher in the ACLF group when

compared with the non-ACLF group (31 ± 6.9 versus 16.4 ±
5.3, P < 0.0001). Etiology of underlying chronic liver disease
in the ACLF group was significantly more likely to be alcohol and hepatitis C accounting for one-third each, whereas
chronic hepatitis C was the most common underlying liver
disease in the non-ACLF group accounting for nearly half
of the group. No significant differences were noted in donor
characteristics, except patients with ACLF received allografts
from recipients with lower BMI.
The mean volume of blood transfused was not significantly
different in the ACLF group [4.2 ± 4.8 units, median, 3 units,
interquartile range, 0–7 units] compared with the non-ACLF
group (3.9 ± 4.8 units, median 3 units, interquartile range,
0–6 units, P = 0.44). In addition, the mean volume of fresh
frozen plasma (5.4 ± 6.0 versus 5.6 ± 6.8 units, P = 0.87) and
platelets (10.2 ± 9.8 versus 11.2 ± 10.5 units, P = 0.31) was
not significantly different.
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(5.3%) had early graft loss as opposed to 13 (12.9%) in the
ACLF group (P = 0.004). Further stratification revealed an
incremental graft loss with ACLF grades: 31 of 589 (5.3%)
in the non-ACLF group, 3 of 50 (6%) with ACLF Grade 1, 6
of 32 (18.8%) with ACLF Grade 2, and 4 of 19 (21%) with
ACLF Grade 3 (P < 0.003).
Graft survival was significantly lower in the ACLF group
compared with the non-ACLF group by Kaplan-Meier survival analysis at 1-year follow-up (P < 0.0001; Figure 2A).
Overall graft survival at 90, 180, 270, 360 days in the nonACLF and ACLF groups based on ACLF severity grades are
displayed in Figure 2B. Among those with ACLF, there was
no difference in graft survival based on number of organ
failures (Figure S1, SDC, http://links.lww.com/TXD/A246).
Graft survival in the non-ACLF group was significantly
better than graft survival in those with ACLF Grade 1 (P =
0.003), ACLF Grade 2 (P = 0.0008), and ACLF Grade 3 (P
< 0.0001) after adjusting for multiple comparisons using the
log-rank test.
Patient Survival by ACLF
Early death defined as death within 90 days was noted in
39 (5.7%) LT recipients. In the non-ACLF group, 27 (4.6%)
had early graft loss as opposed to 12 (11.9%) in the ACLF
group (P = 0.003). Further stratification revealed an incremental increase in mortality with severity of ACLF grades:
27 of 589 (4.6%) in the non-ACLF group, 3 of 50 (6%) with
ACLF Grade 1, 5 of 32 (15.6%) with ACLF Grade 2, and 4 of
21 (19%) with ACLF Grade 3 (P < 0.003).
Overall patient survival within 1-year in the non-ACLF
group was higher compared with the ACLF group of LT recipients (P = 0.0004; Figure 3A). Patient survival within 1-year
based on ACLF severity grades is shown in Figure 3B. Patient
survival in the non-ACLF group was significantly better than
those with ACLF Grade 1 (P = 0.01), ACLF Grade 2 (P =
0.002), and ACLF Grade 3 (P = 0.005) after adjusting for
multiple comparisons using the log-rank test.

FIGURE 2. Cumulative graft survival (death/retransplant) in ACLF
and non-ACLF LT recipients at 1-y follow-up. A, One-y graft survival
by ACLF using Kaplan-Meier survival analysis. B, One-y graft survival
by ACLF Grades using Kaplan-Meier survival analysis. ACLF, acuteon-chronic liver failure; LT, liver transplant.

Early Posttransplant Clinical and Laboratory Profile
During the early post-LT period, significant differences were
noted in the laboratory profile of ACLF and non-ACLF group
(Table 2). LT recipients with ACLF not only needed prolonged
hospitalization (20.9 ± 25.9 versus 11.7 ± 11.4 d, P < 0.0001) but
also had a prolonged length of ICU stay (10.6 ± 19.5 versus 4.2 ±
9 d, P < 0.0001). There was a greater percentage of early (defined
as <90 d) hospital readmissions (>1 admissions) in the ACLF
group, although the differences were not statistically different. Of
the 113 early surgical re-explorations, 27 (26.7%) occurred in
the ACLF group compared with 86 (14.6%) in the non-ACLF
group; these differences were statistically significant (P = 0.002).
The type of early surgical complications/interventions are noted
in Table S1 (SDC, http://links.lww.com/TXD/A246).
Graft Survival by ACLF
Early graft loss defined as graft loss within 90 days was
noted in 44 (6.4%) LT recipients. In the non-ACLF group, 31

Graft and Patient Survival by ACLF and MELD
We further analyzed the combined effect of MELD and
ACLF to estimate survival probability. We categorized the
patients into the following combinations: high ACLF with
high MELD, high ACLF with low MELD, low ACLF with
high MELD, and low ACLF with low MELD. Using the low
ACLF with low MELD group as control, we noted an inferior
graft survival in the high ACLF with high MELD group (P =
0.001), high ACLF with low MELD group (P < 0.0001) as
well as the low ACLF with high MELD group (P = 0.006) at
1-year follow-up (Figure 4A).
Overall patient survival in these combined categories is
shown in Figure 4B. Using the low ACLF with low MELD
group as control, we noted an inferior patient survival in the
high ACLF with high MELD group (P = 0.001), high ACLF
with low MELD group (P = 0.001) as well as the low ACLF
with high MELD group (P = 0.003) at 1-year follow-up.
Predictors of 1-year Graft and Patient Survival
Predictors of 1-year graft and patient survival in the ACLF
group of patients are shown in Table 3. On univariate analysis
using the cox-proportional hazard model, MELD score at LT,
ACLF at LT, pre-LT INR, pre-LT bilirubin, and pre-LT serum
creatinine were significantly associated with 1-year graft and
patient survival.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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FIGURE 3. Cumulative patient survival (death) in ACLF and non-ACLF LT recipients at 1-y follow-up. A, One-y patient survival by ACLF using
Kaplan-Meier survival analysis. B, One-y patient survival by ACLF Grades using Kaplan-Meier survival analysis. ACLF, acute-on-chronic liver
failure; LT, liver transplant.

After adjusting for age at transplant, recipient BMI, and sex
of the patient, multivariate analysis was conducted including
variables significant on univariate analysis and those deemed
clinically significant (Table 4). We tested these variables in 3

independent models: Model 1 included ACLF at LT, Model 2
included MELD at LT, and Model 3 included INR, bilirubin,
and serum creatinine, all at LT. ACLF at LT (Model 1), MELD
score at LT (Model 2), and serum creatinine at LT (Model 3)
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FIGURE 4. Cumulative graft (death/retransplant) and patient survival (death) in all recipients by ACLF and MELD at 1-y follow-up. A, One-y
graft survival by ACLF and MELD using Kaplan-Meier survival analysis. B, One-y patient survival by ACLF and MELD using Kaplan-Meier survival
analysis. ACLF, acute-on-chronic liver failure; MELD, Model for End-Stage Liver Disease.

were significant predictors of graft as well as patient survival
at 1-year after LT. We did not include MELD and ACLF in the
same model due to “multicollinearity.”
The most common cause of graft loss in all groups was
sepsis with 6 (5.9%) in the ACLF group losing their allograft

compared with 16 (2.7%) in the non-ACLF group (Table
S2, SDC, http://links.lww.com/TXD/A246). The number
of retransplants was also significantly higher in the ACLF
group compared with the non-ACLF group (7 [6.9%] versus
32[5.4%]).

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.
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TABLE 3.

Predictors of 1-y graft and patient survival by univariate
cox proportional hazards model patients
Univariate analysis
Parameters
Graft survival
Age at LT
Recipient Gender (Ref=F)
Recipient BMI
Recipient race (Caucasian vs others)
Donor race (Caucasian vs others)
MELD at LT
ACLF at LT
Pre-LT Bilirubin level
Pre-LT ALT level
Pre-LT AST level
Pre-LT INR
Pre-Creatinine level
Pre-LT WBC
Pre-LT platelet count
Pre-LT infection
Donor age
Donor gender (Ref=F)
Donor BMI
CIT
Patient survival
Age at LT
Recipient Gender (Ref=F)
Recipient BMI
Recipient race (Caucasian vs others)
Donor race (Caucasian vs others)
MELD at LT
ACLF at LT
Pre-LT Bilirubin level
Pre-LT ALT level
Pre-LT AST level
Pre-LT INR
Pre-Creatinine level
Pre-LT WBC
Pre-LT platelet count
Pre-LT infection
Donor age
Donor gender (Ref=F)
Donor BMI
CIT

HR (95% CI)

P

0.99 (0.97-1.02)
0.98 (0.61-1.56)
1 (0.96-1.04)
0.76 (0.48-1.21)
0.64 (0.41-1.02)
1.05 (1.02-1.07)
2.55 (1.57-4.13)
1.02 (1.0-1.05)
1 (1-1)
1 (1-1)
1.49 (1.1-2.01)
1.53 (1.24-1.9)
1.02 (0.95-1.1)
1 (1-1)
1.42 (0.71-2.85)
1.01 (0.99-1.02)
0.89 (0.58-1.39)
1.01 (0.97-1.04)
1 (1-1)

0.5
0.93
0.96
0.24
0.06
0.0006
0.0002
0.028
0.98
0.68
0.0094
0.0001
0.51
0.63
0.32
0.42
0.62
0.74
0.78

1.01 (0.98-1.03)
1.02 (0.61-1.71)
1 (0.95-1.04)
0.61 (0.37-1.01)
0.83 (0.51-1.34)
1.05 (1.02-1.08)
2.52 (1.48-4.29)
1.03 (1.01-1.05)
1 (1-1)
1 (1-1)
1.51 (1.1-2.08)
1.55 (1.23-1.96)
1.04 (0.97-1.12)
1 (1-1)
1.32 (0.6-2.88)
1 (0.99-1.02)
0.83 (0.51-1.34)
1 (0.98-1.03)
1 (1-1)

0.66
0.95
0.83
0.053
0.45
0.0009
0.0007
0.015
0.87
0.45
0.011
0.0002
0.22
0.61
0.49
0.79
0.45
0.67
0.88

ACLF, acute-on-chronic liver failure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; CIT, cold ischemic time; HR, hazard ratio;
INR, international normalized ratio; LT, liver transplant; MELD, model for end-stage liver disease;
WBC, white blood cell count.

Survival Outcomes Based on Delta MELD at
Transplant in ACLF Patients
We analyzed the impact of delta MELD (d-MELD) on
graft and patient survival in the 101 patients with ACLF.
We defined d-MELD as the difference in the MELD at the
time of LT and the highest MELD within 4 weeks before LT.
We grouped patients into 3 groups based on d-MELD: negative d-MELD, positive d-MELD, and unchanged d-MELD.
Overall graft and patient survival in these categories is shown
in Figure S2A and S2B (SDC, http://links.lww.com/TXD/
A246), respectively. While there was a noticeable change in
graft survival, it was not statistically significant (P = 0.065),
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but patient survival was noted to be significant (P = 0.012). In
summary, patients with unchanged MELD score had the best
posttransplant survival, and those with a negative d-MELD
(incremental increase in MELD) had inferior graft and patient
survival. Additionally, those with some improvement (positive
d-MELD), reflecting recent ACLF events, still had inferior survival compared with those with unchanged MELD.
Renal Outcomes by Presence of ACLF
The median estimated glomerular filtration rate in the
ACLF group at LT (42 ± 33 versus 85 ± 33 mL/min/1.73m2,
P < 0.0001), 90 days post-LT (55 ± 28 versus 67 ± 28 mL/
min/1.73m2, P < 0.0001), and at 1-year post-LT (57 ± 24
versus 70 ± 24 mL/min/1.73m2, P = 0.008) was significantly
lower at all time points compared with the non-ACLF group.
Although the ACLF group recovered significantly from their
baseline by 90 days post-LT, the median estimated glomerular
filtration rate never reached the median level of the non-ACLF
group by 1-year. Additionally, there was a numerically higher
need for long-term dialysis support post-LT in the ACLF
group compared with non-ACLF group (5 [5.1%] versus 12
[2.1%], P = 0.08).

DISCUSSION
This is one of the first single-center studies examining
LT outcomes and resource utilization among those transplanted for ACLF in the United States using the CANONIC
study criteria. It has been challenging to compare previous
studies such as those using the Asian Pacific Association for
the Study of the Liver Consensus Meeting10,11 or change in
MELD from ACLF,5 due to the heterogeneity of definitions.
The CLIF-SOFA score and subsequent grading classification
serve to standardize the definition of this syndrome for clinical prognosis.
Our study follows a large cohort of ACLF LT recipients
providing insightful perspective regarding outcomes in this
population, who if not transplanted would otherwise have
had a high mortality. We demonstrated that 1-year graft and
patient survival rates were significantly lower in recipients
transplanted with and among the varying grades of ACLF
compared with those transplanted without ACLF. Despite
the lower 1-year graft (78%) and patient survival (82%) rate
among those transplanted in the context of ACLF, this may be
acceptable in patients who otherwise would have died without an LT. When comparing graft and patient survival among
patients with or without ACLF, among the different grades of
ACLF, and among the combined effect of ACLF and MELD,
the trend at 90 days held fairly constant at subsequent time
intervals. This highlights that transplant outcomes in those
transplanted with ACLF are determined early on in the posttransplant setting.
We also note both ACLF Grade 2 and ACLF Grade 3 have
a significantly lower survival compared with the group without ACLF which is supported by the literature demonstrating
lower survival among LT recipients with increasing grades of
ACLF.12 This is in contrast to the study by Artru et al, which
showed that LT recipients with pretransplant ACLF Grade
3 had similar survival compared with recipients with lower
grades of ACLF.4 The discrepancy in survival when our study
is compared with that of Artru et al could be due to timing
of LT. The concept of a “transplantation window” has been
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TABLE 4.

Predictors of 1-y graft and patient survival by multivariate cox proportional hazards model
Model 1
Parameters
Graft survival
Age at LT
Recipient Gender (Ref=F)
Recipient BMI
ACLF at LT
MELD at LT
Creatinine at LT
INR at LT
Bilirubin at LT
Patient survival
Age at LT
Recipient Gender (Ref=F)
Recipient BMI
ACLF at LT
MELD at LT
Creatinine at LT
INR at LT
Bilirubin at LT

Model 2

Model 3

OR (95% CI)

P

OR (95% CI)

P

OR (95% CI)

P

0.99 (0.97-1.02)
0.99 (0.62-1.58)
0.99 (0.96-1.03)
2.53 (1.56-4.12)

0.72
0.96
0.81
0.0002

0.99 (0.98-1.02)
1.02 (0.64-1.64)
0.99 (0.96-1.03)

0.87
0.93
0.76

0.99 (0.97-1.02)
1.02 (0.64-1.64)
0.99 (0.96-1.03)

0.83
0.93
0.72

1.05 (1.02-1.07)

0.0008
1.44 (1.14-1.81)
1.29 (0.90-1.87)
1.00 (0.98-1.03)

0.002
0.17
0.67

1.01 (0.98-1.04)
1.03 (0.61-1.74)
0.99 (0.95-1.04)

0.34
0.90
0.67

1.45 (1.12-1.87)
1.31 (0.88-1.93)
1.01 (0.98-1.04)

0.005
0.18
0.38

1.01 (0.98-1.04)
1.0 (0.69-1.69)
0.99 (0.95-1.04)
2.58 (1.51-4.42)

0.49
0.99
0.74
0.0005

1.01 (0.99-1.04)
1.04 (0.62-1.75)
0.99 (0.95-1.03)

0.32
0.88
0.68

1.05 (1.02-1.08)

0.0005

ACLF, acute-on-chronic liver failure; BMI, body mass index; CI, confidence interval; INR, international normalized ratio; LT, liver transplant; MELD, model for end-stage liver disease; OR, odds ratio.

raised, suggesting a narrow clinical time frame during the
dynamic ACLF process whereby patients with ACLF can be
stabilized and transplanted with acceptable morbidity and
mortality; once this transplant opportunity closes, invasive
interventions become futile.4 It has been proposed that ACLF
grade evaluated between day 3 and day 7 of admission is a
better indicator than admission ACLF for determining prognosis.13 It is uncertain if some of the LT recipients in our study
were outside of this window, as we did not assess changes in
ACLF grade during admission.
The effect of MELD score on posttransplant survival is
unclear with some studies suggesting that patients with higher
MELD scores at time of transplant may have lower survival,14,15
while others show no association between MELD score and
posttransplant outcomes.16,17 We observed MELD score at LT
is a significant predictor for graft survival both on univariate
and multivariate analysis. When evaluating the combined effect
of ACLF and MELD scores, we found that the 90-day graft
and patient survival of the group with low ACLF (no ACLF or
ACLF 1) and high MELD (MELD ≥30) was not far off from
those patients with low ACLF and low MELD scores (90%
versus 95% for both graft and patient survival, respectively).
Overall, this suggests that the presence and severity of
ACLF, specifically the presence of multiple organ failures,
drives morbidity and mortality in this population. Thus, factors that are not included in the MELD scoring system may
play a pivotal role in influencing outcomes in this critically ill
population. The occurrence of nonhepatic organ dysfunctionshock, respiratory failure, cerebral failure, and other factors
that are not captured in the MELD score, negatively impact
the natural history of these patients early in the posttransplant
period. Organ failures captured by the MELD scoring system
may be rapidly reversible with transplantation, but recovery
from the established extrahepatic organ failures reflected in
ACLF may be slower and somewhat independent of liver
function. It is no wonder that we found patients with high

ACLF regardless of MELD had a significantly lower 90-day
graft and patient survival compared with patients with any
range of MELD score with low ACLF. Interestingly, the lowest 90-day graft and patient survival was in those with high
ACLF and low MELD scores, although this group was small
in number. Larger, prospective studies are needed to further
clarify the combined effect of MELD and ACLF on survival.
Another important observation noted was the significant
renal dysfunction at 1-year follow-up in the ACLF group compared with non-ACLF group. Additionally, the need for dialysis was also significantly higher in the ACLF patients at 1-year
post-LT. This finding is novel and has not been reported in
earlier studies. Clearly, patients with ACLF need closer monitoring during their post-LT period, and strategies should be
devised to prevent worsening of renal dysfunction and need
for renal replacement therapy in this vulnerable group.
Nationwide, there has been a 3-fold increase in patients
with liver disease who meet the criteria for ACLF and consequently a 5-fold increase in costs associated with admission for ACLF, now reaching $1.7 billion dollars annually.18
In this study, we observed LT recipients with ACLF to have
higher healthcare resource utilization after transplant, which
is similar to that found in other studies.4,12,15 This group had
increased operative blood transfusion, longer length of ICU
stay posttransplant, longer overall hospital stay, and increased
readmissions. Readmissions, particularly those in the first 6
months after LT, have been shown to predict mortality.19 The
relatively higher surgical re-exploration in the ACLF cohort
(26.7%) compared with the non-ACLF LT recipients (14.6%)
may reflect the challenging nature of any surgical intervention
in this critically ill group.
Our study’s strengths include its large sample size, as we
were able to evaluate demographic and clinical information
and outcomes of 690 LT recipients at a single transplant
center. Limitations include those inherent in any retrospective
study in which confounding, and selection biases can occur.

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.

This is particularly true as we did not examine the course
of ACLF in patients who were not transplanted. We did not
have information on the evolution of ACLF during the pretransplant phase of each recipient’s or transplant candidate’s
admission. Also, patients' clinical and demographic characteristics, as well as clinical and immunosuppression practices
vary among transplant centers and could influence results. As
such, results of this study needs external validation.
In summary, although LT is an effective treatment with
ACLF, 1-year mortality and graft loss is higher for LT recipients with ACLF compared with that of non-ACLF LT recipients. The severity of ACLF correlated significantly with
posttransplant mortality and graft loss. Moreover, there are
higher rates of complications and resource utilization among
transplanted patients with ACLF.
The groups with both high ACLF regardless of MELD had
the lowest graft and patient survival. Larger and more controlled prospective studies are needed to assess the combined
effect of MELD score and ACLF in determining prognosis
after transplant in these critically ill patients. Our findings
highlight that MELD score for the most part is just a number
indicating severity of liver damage and is quickly reversible
with organ transplant, but the presence of multiple nonliver
organ failures reflected in ACLF may independently affect the
viability of the new liver as well as the patient in the immediate
posttransplant period. Given the very high mortality without
LT in those with advanced ACLF and the significantly worse
posttransplant graft and patient survival compared with those
without ACLF, centers will need to carefully weigh the risks
and benefits before proceeding with transplantation in these
select patients. Future research should focus on prognostication with and without LT in those with ACLF, early diagnosis and aggressive management to improve ACLF scores with
medical therapy, and determination of the optimal timing of
LT in this high-risk population. Meanwhile, given the scarcity
of liver grafts and lower, albeit acceptable graft and survival
outcomes in this high-risk population, it is advisable to carefully risk-stratify this population. Further, when transplant
is pursued in this population, we should anticipate increased
costs and resource utilization to support this group during the
challenging posttransplant period where complications are
likely to develop.
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